US 8492359

I'll search for authoritative information on this specific patent number.

Let me verify the CAFC docket and the full claim set.

Let me pull the actual claim language from a patent text source.

US Patent 8,492,359 — Verification Summary

Sourcing note: I searched Google Patents, FreePatentsOnline/Justia family records, USPTO PTAB filings, court dockets (CourtListener, Docket Alarm, archive.org CAFC records), and the Federal Circuit briefing for No. 26‑1581. Everything below is grounded in those results. Where I could not retrieve verbatim text I say so explicitly.

Bibliographic data (verified)

The source patent text confirms "US 201113253917A," "Prior art date 2008‑04‑15," and status "Active, expires 2029‑06‑13."

Abstract (verbatim, as published)

"The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid‑lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP."

Technical thrust

The patent is a lipid‑nanoparticle (LNP) formulation patent — the "SNALP" family. Its contribution is a claimed molar‑ratio window for the four lipid components (cationic lipid / non‑cationic lipid / PEG‑lipid conjugate, with cholesterol or phospholipid+cholesterol), which the specification asserts gives a >10‑fold efficacy gain over the earlier "2:30" formulation (Example 4) and superiority over the "2:40" formulation (FIG. 2). Worked examples center on the "1:57 SNALP" (≈1.4% PEG‑cDMA; 57.1% DLinDMA; 7.1% DPPC; 34.3% cholesterol) and "1:62 SNALP" (≈1.5% PEG‑cDMA; 61.5% DLinDMA; 36.9% cholesterol) formulations.

Independent claims — plain‑language overview

Important qualification on verbatim text. The full patent text I was given is truncated mid‑specification and does not include the claims. I could not retrieve the verbatim claim set of the '359 patent from an authoritative full‑text source in this session. What I can verify is the claim structure of its closest continuation, US 9,364,435 (application 14/462,441), which the CAFC opening brief in Arbutus v. Moderna, No. 26‑1581 reproduces verbatim and which shares the identical specification. The '435 claim 1 reads:

"1. A nucleic acid‑lipid particle comprising: (a) a nucleic acid; (b) a cationic lipid comprising from 50 mol % to 85 mol % of the total lipid present in the particle; (c) a non‑cationic lipid comprising from 13 mol % to 49.5 mol % of the total lipid present in the particle; and (d) a conjugated lipid that inhibits aggregation of particles comprising from 0.5 mol % to 2 mol % of the total lipid present in the particle."

The Delaware claim‑construction record confirms that the '359 patent's claims 1, 7, 9, 10, 11, 12, 13, 18, and 19 recite the same "mol % of the total lipid present in the particle" limitation (Joint Claim Construction Chart, D. Del. 1:22‑cv‑00252, D.I. 129). This strongly corroborates that '359 claim 1 is the same genus claim, but I flag it as corroborated inference rather than verbatim confirmation of the '359 text.

Working from that verified family structure, the independent claims are:

1. Claim 1 — The composition genus. A nucleic acid‑lipid particle containing (a) a nucleic acid (e.g., siRNA), (b) 50–85 mol % cationic lipid, (c) 13–49.5 mol % non‑cationic lipid, and (d) 0.5–2 mol % of an aggregation‑inhibiting conjugated lipid (e.g., PEG‑lipid). In plain terms: an LNP defined by its lipid molar ratio window.

2. Claim 14 — Pharmaceutical composition. Claim 1's particle plus a pharmaceutically acceptable carrier. In plain terms: a drug product made from the particle.

3. Claim 15 — Introduction into a cell. Contacting a cell with the claim‑1 particle. In plain terms: using the particle to get nucleic acid into cells (in vitro workhorse claim).

4. Claim 16 — In vivo delivery. Administering the claim‑1 particle to a mammalian subject. In plain terms: using the particle as an in‑vivo nucleic‑acid delivery vehicle.

5. Claim 17 — Method of treatment. Administering a therapeutically effective amount of the claim‑1 particle to a mammal in need (dependent claims 18–20 narrow to viral infection, liver disease/disorder, and cancer respectively).

The dependent claims narrow along familiar lines: silencing‑RNA types (siRNA/aiRNA/miRNA), phospholipid + cholesterol mixtures, DPPC/DSPC selection, phospholipid at 3–15 mol %, cholesterol at 30–40 mol %, PEG‑DAG/PEG‑DAA conjugates (PEG‑DMA, PEG‑DSA), and ≥1 mol % conjugate.

Litigation posture (as of the search date)

• Federal Circuit No. 26‑1581, Arbutus Biopharma Corp. v. Moderna, Inc. — appeal from D. Del. 1:22‑cv‑00252‑JDW (Judge Joshua D. Wolson). The Joint Appendix confirms the complaint attached "Exhibit B, United States Patent No. 8,492,359, dated July 23, 2013" as an asserted patent. The consolidated appeal issue is the § 1498(a) government‑contractor affirmative defense; the district court granted summary judgment on February 2, 2026 (D.I. 697/698) and entered final judgment March 4, 2026 (D.I. 758). Oral argument was set for the November 2026 calendar (order of August 24, 2026, D.I. 63). The U.S. filed an amicus brief supporting Moderna (June 19, 2026) and moved to participate at argument. This is a § 1498 appeal, not a validity or claim‑construction appeal.
• Other asserted‑patent cases listed on the Google Patents family page: N.Y.S.D. 1:22‑cv‑02229 (Acuitas v. Genevant), D.N.J. 3:23‑cv‑04200 and 2:23‑cv‑01876, and D. Del. 1:22‑cv‑00252.

Explicit uncertainties

1. Verbatim claim text of the '359 patent — not retrieved; the claim‑1 language above is from the sibling '435 patent and is corroborated (not confirmed) for '359 by the joint claim construction chart.
2. Whether '359 claim 1 uses "about" — the Delaware chart notes a dispute framed as "[w]here the asserted claims do not recite 'about mol %'"; I cannot confirm which side of that line the '359 claims fall on.
3. Issue date footnote — the front page carries a * footnote ("Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 59 days. This patent is subject to a terminal disclaimer."). The * asterisk convention typically signals post‑issuance certificate activity; I did not confirm the specific certificate.
4. Term/expiry — 2029‑06‑13 is Google Patents' listing; the Patsnap litigation record states estimated expiry April 15, 2029. These differ; I would defer to USPTO PatentCenter/PAIR for the operative date.

I'll research this systematically. Let me start by searching litigation databases and the specific case numbers listed on the patent record.

I have substantial data. Let me verify the remaining cases and the appellate docket.

Litigation involving US Patent 8,492,359 ("Lipid formulations for nucleic acid delivery")

Bottom line: Yes — US 8,492,359 ("the '359 patent") has a substantial litigation history. It is one of the three "Molar Ratio Patents" in the Arbutus LNP family (along with US 9,364,435 and US 11,141,378) and has been asserted in at least two affirmative infringement actions and challenged in one declaratory-judgment action. The highest-profile action was resolved by a global settlement in March 2026.

A threshold note on dates: I retrieved these materials on a system date of 2026‑09‑30, while your prompt states 2026‑04‑26. I flag this because several sources retrieved are dated after April 26, 2026. Statuses below reflect the latest retrievable information.

1. Arbutus Biopharma Corp. and Genevant Sciences GmbH v. Moderna, Inc. and ModernaTX, Inc.

Key procedural history in that case:

• A jury trial had been scheduled for March 9, 2026. On February 2, 2026, Judge Wolson ruled that "for the Government" under § 1498 requires use for the benefit of the Government itself, keeping essentially all of Moderna's government-contract vaccine sales in the case, and held that Arbutus's removal of "about" from its claimed lipid ranges during prosecution invoked prosecution history estoppel, barring DOE infringement. On February 17–18, 2026, the court granted in part Arbutus's summary-judgment motion: it barred Moderna's obviousness defenses (IPR estoppel under 35 U.S.C. § 315(e)(2) plus issue preclusion) and its derivation defense, but permitted Moderna's enablement defense to go to a jury.
• On March 3, 2026, the parties filed a proposed consent judgment, and on March 4, 2026, the court entered the consent judgment terminating the case. CourtListener reports the termination as to "Patent/Trademark Number(s) US 8,058,069 B2; US 8,492,359 B2; US 8,822,668 B2; US 9,364,435 B2; US 9,504,651 B2," and a notice of appeal to the Federal Circuit.
• Source: CourtListener Docket No. 63119229 (D. Del. 1:22-cv-00252); IPWatchdog, "Delaware Court Narrows Moderna's Invalidity Defenses Ahead of Arbutus LNP Patent Trial" (Feb. 18, 2026); Lexology/Pearce IP settlement coverage (Mar. 3, 2026); Roivant/Arbutus 10-K and 10-Q disclosures.

2. Arbutus Pharma Corp. (f/k/a Arbutus Biopharma Corp.) and Genevant Sciences GmbH v. Pfizer Inc. and BioNTech SE ("the Pfizer Action")

Sources: CourtListener Docket 67142175 (D.N.J. 3:23-cv-01876), Order on Motion to Amend/Correct (D.I. 289); Arbutus investor disclosure "Patent Infringement Litigation vs. Pfizer and BioNTech"; Roivant Sciences 10-K disclosure.

3. Acuitas Therapeutics Inc. v. Genevant Sciences GmbH and Arbutus Biopharma Corp. (S.D.N.Y.)

Sources: DrugPatentWatch case entry (S.D.N.Y. 1:22-cv-02229); CourtListener Docket 63169706, D.I. 79 (notice of voluntary dismissal); D.I. 48, D.I. 69, D.I. 80 on the same docket.

4. Acuitas Therapeutics Inc. v. Genevant Sciences GmbH and Arbutus Biopharma Corp. (D.N.J. refiling)

On August 4, 2023, Acuitas refiled its declaratory-judgment action against Genevant and Arbutus in the District of New Jersey, again seeking declarations that Comirnaty® does not infringe, and that, ten Arbutus patents are invalid. Acuitas's stated reason was that Arbutus/Genevant had chosen to litigate the same patents against Pfizer/BioNTech in New Jersey and had refused to consent to transfer the S.D.N.Y. case.

Important qualification: I could not verify the D.N.J. case number for this Acuitas refiling from the sources retrieved. Google Patents' litigation data for this patent family lists a New Jersey District Court case, 3:23-cv-04200, which is temporally consistent with the August 4, 2023 refiling — but I am not asserting that 3:23-cv-04200 is the Acuitas refiling, because I did not confirm it. Treat that identification as an unverified inference requiring PACER confirmation.

Related proceedings that do not assert US 8,492,359

• Moderna's § 1498 appeal (Federal Circuit). Google Patents' litigation data for this family lists a Court of Appeals for the Federal Circuit case No. 26-1581, which corresponds to Moderna's appeal of the Delaware district court's rejection of its § 1498 government-contractor defense in 1:22-cv-00252. I was unable to independently verify the docket number 26-1581; Roivant's disclosure confirms only that Moderna filed a notice of appeal in March 2026, that briefing was expected to complete in July 2026, and that oral argument is expected in 2027. If Moderna prevails in whole, no contingent payment is owed; if it loses in whole, up to $1.3 billion becomes payable.
• International actions (2025). On March 3, 2025, Genevant and Arbutus filed five suits against Moderna: Federal Court of Canada File No. T-704-25 (CA 2,721,333); Tokyo District Court Case No. 2025 (Wa) 70079 (JP 5,475,753); Switzerland Case O2025 002 (EP 2,279,254); UPC Case UPC_CFI_191/2025 (formerly 10280/2025) (EP 2,279,254); and UPC Case UPC_CFI_192/2025 (formerly 10284/2025) (EP 4,241,767). EPO oppositions by Moderna against EP 2,279,254 and EP 4,241,767 are also listed. These assert foreign family members, not US 8,492,359. All were resolved by the March 3, 2026 settlement.
• PTAB. The district court record reflects that Moderna previously challenged the '435 patent in an IPR and lost (final written decision rejecting invalidity; the Federal Circuit dismissed Moderna's appeal for lack of standing) — this is what grounded the § 315(e)(2) estoppel ruling. I did not find a confirmed IPR petition or final written decision specifically directed to US 8,492,359, and I decline to infer one. Caution: search results surfaced an unrelated IPR2024-00613 concerning a different "'235 patent" in an Eastern District of Texas networking dispute (trial set March 3, 2025) — that is not this patent and should not be conflated with it.

Summary table

Caveats you should carry forward

1. Unverified identifications: the D.N.J. number for the Acuitas refiling, the CAFC docket number 26-1581, the correct D.N.J. case number for the Pfizer Action (2:23- vs. 3:23-cv-01876), and the existence/scope of any IPR on the '359 patent. Confirm each against PACER/PTAB before relying on it.
2. Scope of the Google Patents "family has litigation" list: those five entries are family-level, not patent-level, and include the two U.S. D.N.J. entries and the CAFC entry discussed above.
3. The '359 patent was originally assigned to Protiva Biotherapeutics Inc. and is now held by Arbutus Biopharma Corporation (by merger); Genevant Sciences GmbH is the co-plaintiff/exclusive licensee in the LNP enforcement campaign.

PTAB / AIA Trial Proceedings — US 8,492,359 ("Lipid formulations for nucleic acid delivery")

Sourcing note. The canonical list in the structured "PTAB proceedings on file" block (USPTO Open Data Portal) shows no AIA trial proceedings for this patent. I was asked to use web search to fill in details and to flag anything the ODP may not have indexed. I searched PTAB decisions/tracker sources, the litigation record (D. Del., D.N.J., S.D.N.Y.), and Arbutus's SEC disclosures. Nothing surfaced that contradicts the ODP result. I could not query PTAB E2E (ptacts.uspto.gov) or the PTAB API directly in this session, so my corroboration is documentary rather than a live docket query.

Proceedings overview

Total AIA trial proceedings on US 8,492,359: zero. No IPRs, no PGRs, no CBMs — not instituted, not denied, not settled, not pending. The patent's litigation history is entirely Article III (D. Del., D.N.J., S.D.N.Y., plus this year Canadian Federal Court and UPC actions), and every PTAB challenge in this patent family has been aimed at its siblings, not at the '359 patent: Moderna's three IPRs (IPR2018‑00680, IPR2018‑00739, IPR2019‑00554) hit US 9,404,127, US 9,364,435, and US 8,058,069 respectively.

Bottom-line defensive posture: This is not a "hardened" patent and it is not a "dead" patent — it is an untested patent, and that cuts in the defendant's favor. Every claim of the '359 patent is live; nothing has been canceled; nothing has been adjudicated patentable at the Board either. A defendant facing assertion today has a clean, unused IPR runway, and the family's IPR record (including the July 2020 defeat in IPR2019‑00554 and the mixed result in IPR2018‑00739) shows the technology is challengeable even if the broadest sibling claim survived.

Proceedings on US 8,492,359

None to report. There is no proceeding number to list, no institution decision, no FWD, no estoppel, and no PTAB appeal attributable to this patent.

Why the absence is structural, not an oversight

• Procedural posture. The '359 patent issued 2013‑07‑23 from an application filed 2011‑10‑05 claiming priority to 2008‑04‑15. It is a pre‑AIA patent (effective filing date before 2013‑03‑16). That makes PGR unavailable (AIA § 6; 35 U.S.C. §§ 321–329 apply to first‑inventor‑to‑file patents) and CBM inapplicable (no financial‑product/service claims). IPR is the only AIA trial vehicle ever available against it, and the § 311(c) nine‑month waiting period expired in April 2014.
• The family IPRs deliberately skipped it. The Board's own related‑proceedings recitation confirms the mapping: IPR2018‑00680 → US 9,404,127 B2; IPR2018‑00739 → US 9,364,435 B2; IPR2019‑00554 → US 8,058,069 B2. See the Decision on Institution in IPR2019‑00554 at 2–3, https://www.bigmoleculewatch.com/wp-content/uploads/sites/2/2023/12/PTAB-IPR2019-00554-Decision-on-Institution.pdf. Arbutus's own SEC reports and the Acuitas declaratory‑judgment complaint enumerate those same three IPRs and treat them as the complete set. The Moderna counterclaim in D. Del. sought declaratory judgment of invalidity on the '359 patent in court, not at the PTAB.
• The other two asserted parties didn't file IPRs against it either. Pfizer/BioNTech's '359 invalidity case has been litigated as a district‑court defense — most recently via a motion to amend invalidity contentions to add a § 112 indefiniteness theory against the "Molar Ratio Patents" (the '359 and '378 patents), granted 2026‑01‑27 in D.N.J. Civil Action No. 23‑1876 (ZNQ), https://archive.org/download/gov.uscourts.njd.[510890](/patent/510890)/gov.uscourts.njd.510890.289.0.pdf. That is a party that does use IPRs (it challenged Moderna's US 10,702,600 in IPR2023‑01358), so its choice not to petition against '359 is a signal, not an accident.

Where you can find the FWDs — the three family proceedings (context only; these are not proceedings on '359)

FWD documents: https://www.bigmoleculewatch.com/wp-content/uploads/sites/2/2023/12/PTAB-IPR2019-00554-Final-Written-Decision.pdf (IPR2019‑00554) and the Decision on Institution linked above. The controlling appellate dispositions are ModernaTx, Inc. v. Arbutus Biopharma Corp., Nos. 2020‑1184, ‑1186 (Fed. Cir. 2021‑12‑01) (appeal dismissed for lack of standing as to the '435 patent; cross‑appeal affirmed) and No. 2020‑2329 (Fed. Cir. 2021‑12‑01) (affirming the '069 FWD on the merits).

⚠️ Contradiction to flag against the earlier-generated section

The earlier "Patent summary" section's characterization of '359 claim 1 is, in my assessment, wrong — and the error direction matters for a defendant.

That section inferred from the sibling '435 patent that '359 claim 1 is the broad genus claim reading "(b) a cationic lipid comprising from 50 mol % to 85 mol % … (c) a non‑cationic lipid comprising from 13 mol % to 49.5 mol % … (d) … from 0.5 mol % to 2 mol %."

The litigation record quotes '359 claim 1 verbatim and differently. From the S.D.N.Y. answer (Defendants admitting claim 1's text):

"[a] nucleic acid‑lipid particle comprising: (a) a nucleic acid; (b) a cationic lipid comprising from 50 mol % to 65 mol % of the total lipid present in the particle; (c) a non‑cationic lipid comprising a mixture of a phospholipid and cholesterol or a derivative thereof, wherein the phospholipid comprises from 3 mol % to 15 mol % of the total lipid present in the particle and the cholesterol or derivative thereof comprises from 30 mol % to 40 mol % of the total lipid present in the particle; and (d) a conjugated lipid that inhibits aggregation of particles comprising from 0.5 mol % to 2 mol % of the total lipid present in the particle."

Source: https://storage.courtlistener.com/recap/gov.uscourts.nysd.[576814](/patent/576814)/gov.uscourts.nysd.576814.78.1.pdf

This is independently confirmed by Acuitas's DJ complaint, which alleges non‑infringement because the accused COMIRNATY LNP "does not comprise 'a cationic lipid comprising from 50 mol % to 65 mol % of the total lipid present in the particle' as required by the claims of the '359 patent" (https://storage.courtlistener.com/recap/gov.uscourts.nysd.576814/gov.uscourts.nysd.576814.78.1.pdf and the Acuitas DJ complaint at ¶¶ 108–113).

Practical consequences of the correction:

1. '359 claim 1 is a four‑component, phospholipid‑mandatory claim with a 50–65 mol % cationic‑lipid window — it is not the 50–85 mol % genus. That makes it the narrow sibling of the '069 patent (claim 1: 50–65 mol % cationic, phospholipid 4–10 mol %, cholesterol 30–40 mol %) rather than the broad '435‑style genus.
2. The '359 phospholipid range (3–15 mol %) is broader than the '069 range (4–10 mol %) that survived IPR2019‑00554. So the IPR2019‑00554 win does not read across to invalidate '359 claim 1, and the '359 claim was not a "free rider" on the '069 result.
3. For infringement analysis, the operative number for a Moderna/Pfizer‑type LNP is the cationic lipid mol %, and the disputed construction is "mol %" itself — a term construed in D.N.J. on 2025‑09‑09 in Arbutus/Genevant v. Pfizer/BioNTech.

I have not verified the '359 patent's full printed claim set (claims 2–20) verbatim; the earlier section's claim count of 20 and its list of claims reciting "mol % of the total lipid present in the particle" are plausible but unverified. Treat claim 1's text as verified; treat the rest as open.

Strategic summary

Claim status on US 8,492,359. Canceled: none. Sustained (adjudicated patentable by the Board): none. Untested: all claims. There is no PTAB narrowing, no certificate of correction cancelling claims, and no reissue. The only public adjudications touching this claim family are: (i) all claims of '127 canceled; (ii) claims 1–6, 9, 12, 14–15 of '435 canceled and claims 7, 8, 10, 11, 13, 16–20 sustained; (iii) all claims of '069 sustained. Because '359 claim 1 is textually distinct from each (phospholipid‑mandatory, 50–65 mol % cationic, 3–15 mol % phospholipid), none of those dispositions is dispositive of '359.

Estoppel landscape. Section 315(e)(2) estoppel is patent‑specific and petitioner‑specific. No IPR was instituted on '359, so no estoppel attaches to the '359 patent from Moderna's three sibling IPRs — there is no "grounds raised or reasonably could have raised" bar on the '359 patent against any party. Two caveats worth diligence:

• Arbutus has argued the opposite position in the Moderna case: the D. Del. summary‑judgment order of 2026‑02‑17 (D.I. 744) recites that "Plaintiffs' claims that IPR estoppel and issue preclusion bar" certain defenses included the '359 and '378 patents, and the motion was GRANTED IN PART and DENIED IN PART on those items. https://www.courtlistener.com/docket/63119229/744/arbutus-biopharma-corporation-v-moderna-inc/. I could not determine from the retrieved text which sub‑issues were granted versus denied, and I would not represent to a client that the court held either way without pulling the full opinion. Verify before relying on it.
• Moderna and Arbutus have since settled (reported immediate payment of $950 million, with ~$1.3 billion contingent on the § 1498(a) appeal; Moderna taking a global nonexclusive license and a covenant not to sue on certain patents). This coexists with the pending § 1498 appeal at the Federal Circuit (No. 26‑1581, argument Nov. 2026) — consistent with the earlier section. Note the date tension: the earlier section dates final judgment to 2026‑03‑04 and the MBHB summary of the settlement is published as 2026‑03‑12, which cannot both describe a July 2026 payment; I flag this rather than reconcile it.

Available grounds. For a defendant being asserted against today, the entire § 102/§ 103 IPR toolkit on the '359 patent is unused. § 315(b) is the gate: any defendant served with a complaint more than one year ago is time‑barred from petitioning. Pfizer/BioNTech (D.N.J. 3:23‑cv‑01876 and 2:23‑cv‑01876, filed 2023‑04‑04) and Acuitas (S.D.N.Y. 1:22‑cv‑02229, filed 2022‑03‑18) are almost certainly § 315(b)‑barred as to the '359 patent; a new defendant is not. The '435 and '069 proceedings also generated a § 325(d) record (same/similar art previously before the Office) that a new petitioner should address pre‑emptively, since the '196 PCT, '189 publication, '554 publication, Lin, and Ahmad are precisely the art Arbutus has already defended against.

Pattern signals. Moderna filed three IPRs against Arbutus's LNP family (2018‑02/03 and 2019‑01) but pointedly not at '359, and then litigated '359 in court; Pfizer/BioNTech did the same. No defensive aggregator (e.g., Unified Patents) appears anywhere in the chain — the litigation is all operating‑company‑v‑operating‑company. Arbutus/Genevant have litigated hard across four fora (D. Del., D.N.J., S.D.N.Y., Fed. Cir.) and this year added Canada and the UPC. The patent owner is not a serial PTAB appellant because it has rarely lost at the Board — the one loss ('127) was appealed and affirmed.

Recommended next steps

1. If you are a defendant with a § 315(b) window open: this is the rare asserted LNP patent with a completely clean PTAB slate. There is no FWD to distinguish, no estoppel, and no claim construction at the Board. Budget for an IPR that attacks the '359-specific limitations — the 3–15 mol % phospholipid range and the 50–65 mol % cationic range — rather than recycling the '069/'435 art wholesale, because the '069 FWD shows the Board is receptive to Arbutus's "unpredictability of molar‑ratio changes" argument when the art is a bare overlapping‑range obviousness theory.
2. Pull the actual documents before relying on anyone's summary (including the earlier section's): the full '359 claim set from the patent's own text; the D. Del. D.I. 744 opinion (IPR estoppel/issue preclusion holding as to '359 and '378); and the D.N.J. claim construction of "mol %," "lipid vesicle," "fully encapsulated," and "consisting essentially of."
3. Confirm the negative directly at PTAB E2E (https://ptacts.uspto.gov/) by patent number 8,492,359 — the ODP "no proceedings" result is the canonical answer, but a five‑minute E2E query closes the loop on anything filed and not yet indexed. If you find anything, the analysis changes and the ODP default should be revisited.
4. Track the Federal Circuit. No PTAB appeal concerns the '359 patent; the live appellate issue (No. 26‑1581) is the § 1498(a) government‑contractor defense, which is a who‑pays question, not a validity or claim‑construction question. It does not create or destroy invalidity defenses against '359, but it materially affects settlement leverage with any party making vaccines for the U.S. Government.
5. Do not cite claims 1–6, 9, 12, 14–15 of the '435 patent or the claims of the '127 patent in any demand letter as if they belonged to '359. Those are the canceled claims, and they are on different patents. Conversely, do not assume the '359 claims died with the '435 claims — they did not.

I'll research the assignment record for this patent across USPTO sources and litigation/ownership databases.

Let me dig for the recorded reel/frame data and the inventor assignment details.

I hit the tool-call limit before I could pull the raw reel/frame records directly from the USPTO Assignment Center interface. Below is the ownership reconstruction built from what I did retrieve — Google Patents' legal‑events feed (which mirrors Assignment Center records), the D.N.J. and D. Del. complaints, Arbutus's SEC filings, and the PTAB mandatory notices. I flatly could not retrieve reel/frame numbers or execution dates, and I say so rather than invent them.

Inventors

Sourcing: the '359 face page ((72) Inventors: Edward Yaworski, Maple Ridge (CA); Kieu Lam, Surrey (CA); Lloyd Jeffs, Delta (CA); Lorne Palmer, Vancouver (CA); Ian MacLachlan, Mission (CA), (73) Assignee: PROTIVA BIOTHERAPEUTICS, INC., Burnaby, BC (CA)), reproduced in the D. Del./D.N.J. complaints (see the Acuitas v. Genevant complaint copy of the '435 at docketalarm; and the Fed. Cir. opening brief PDF which reprints the '359/'435 front pages). The EPO/INPI record for the sibling EP 2 279 254 confirms the same five inventors with Protiva (Burnaby, BC V5J 5J8) as applicant.

Departure pattern — no fire-sale precursor found.

• All five inventors assigned to Protiva (D.N.J. 3:23‑cv‑04200 Am. Compl. ¶62: "All the named inventors assigned the '359 patent…"; the SDNY Acuitas complaint repeats the identical recital for the sibling patents).
• This is a stable, long-tenured bench, not a team that bailed out post‑filing. The same five names recur across the entire Protiva/Arbutus LNP family — '069, '359, '668, '435, '378 — and Lloyd Jeffs / Lorne Palmer appear again on the '651, '098 and '272 patents. Ian MacLachlan's patentleaderboard profile lists 51 patents at Protiva Biotherapeutics.
• Note for context, not a signal: Cory Giesbrecht, a co-inventor on adjacent family members ('651, '098), is deceased — acknowledged in Arbutus's 3 March 2026 press release. He is not an inventor on the '359 patent.

Original assignee

Protiva Biotherapeutics, Inc., Burnaby, British Columbia, Canada — named on the face of the issued patent and recorded as the applicant for the pre‑grant publication US 2012/018183581 A1.

• Line of business: clinical‑stage RNAi therapeutics / LNP delivery technology. Protiva was the originator of the "SNALP" (stable nucleic acid‑lipid particle) platform at the center of this patent. The foundational Protiva work is the Zimmermann et al. Nature ApoB paper (affiliations credited to "Protiva Biotherapeutics, Burnaby, BC, Canada").
• Did they ship a product embodying the claims? Not branded by Protiva. But the claims are embodied in a commercially approved product: Onpattro (patisiran), Alnylam's siRNA‑LNP drug, uses this LNP technology under license. Arbutus's 10‑K describes tiered royalties of 1.00 %–2.33 % on global Onpattro net sales under the LNP License Agreement with Alnylam — i.e., a practicing, royalty‑bearing product. Arbutus later monetized that royalty stream to OMERS (effective 1 Jan 2019, ~$20 M gross).
• Current status: Not operating as a separate entity. Per Arbutus's IPR mandatory notices (IPR2018‑00739, 19 July 2018): "Protiva Biotherapeutics, Inc. existed as a wholly‑owned subsidiary of Arbutus Biopharma Corporation. Protiva Biotherapeutics, Inc. was amalgamated into Arbutus Biopharma Corporation in January 2018." No bankruptcy. The parent chain is Tekmira Pharmaceuticals Corporation → renamed Arbutus Biopharma Corporation (2015); Protiva was already described as Tekmira's subsidiary by mid‑2009 per Arbutus's 10‑K ("we and our subsidiary Protiva…").

Assignment timeline

Important limitation. Google Patents' legal‑events feed for US 8,492,359 shows exactly two post‑issue recorded ownership events, both carrying a 2018‑02‑21 date. I could not open the underlying Assignment Center abstract pages, so I have no reel/frame numbers, no execution dates, and no correspondent-of-record data for either entry. Everything below is what the feed supports; where a field is blank, that means not retrieved, not "none."

• 20??‑??‑?? (executed, not retrieved) / recorded 2018‑02‑21 — Reel not retrieved/NNNN

  • Conveyance: Assignment of Assignors' Interest
  • Assignor: Yaworski, Edward; Lam, Kieu; Jeffs, Lloyd; Palmer, Lorne; MacLachlan, Ian (all five named inventors)
  • Assignee: Protiva Biotherapeutics, Inc.
  • Correspondent: not retrieved (see caveat under Signal 3 below re: Kilpatrick Townsend & Stockton LLP) — could not tie to this record
  • Context: Ordinary inventor-to-employer assignment. Note the Google feed dates this as recorded 2018‑02‑21, which is almost certainly the batch‑recording date rather than the execution date; a 2008/2009 execution is far more likely given the '069 ancestor was already assigned to Protiva. Flagging as a date ambiguity in the feed, not a real transfer in 2018.

• 20??‑??‑?? (executed, not retrieved; entity amalgamation occurred January 2018) / recorded 2018‑02‑21 — Reel not retrieved/NNNN

  • Conveyance: Merger (Google's label; operationally a Canadian amalgamation)
  • Assignor: Protiva Biotherapeutics Inc.
  • Assignee: Arbutus Biopharma Corporation
  • Correspondent: not retrieved
  • Context: Internal corporate reorganization / upstream parent absorption — Protiva (wholly‑owned sub) amalgamated into its parent Arbutus. No consideration, no change in ultimate control, no third party.

No further recorded ownership events. There is no record of any assignment to a licensing LLC, SPV, or aggregator. Title has run Protiva → (amalgamation) → Arbutus and stopped there. In particular: the Genevant Sciences relationship is a license, not an assignment — the D. Del. complaint is explicit: "All are assigned to and owned by Arbutus, and, at all times since Arbutus and Genevant entered into a license agreement, Genevant has held Exclusive Rights to all of the Asserted Patents in various fields of use…" (§30). Genevant sues as exclusive licensee/co‑plaintiff; Arbutus keeps the title.

Timeline diagram

timeline
    title Ownership of US 8492359
    2008 : Protiva files provisional 61 045 228
    2009 : Application 12 424 367 filed
    2011 : Continuation 13 253 917 filed Oct 5
    2013 : Patent 8492359 issues Jul 23
    2018 : Inventor assignments recorded Feb 21
         : Protiva amalgamated into Arbutus
    2022 : Arbutus and Genevant sue Moderna
    2023 : Arbutus and Genevant sue Pfizer BioNTech
    2026 : 2.25B dollar Moderna global settlement

NPE / troll-pattern signals

Methods note: I have no reel/frame citations available, so every call below is grounded in litigation pleadings, SEC filings, and PTAB notices rather than assignment indexing. I would not stake a validity-critical opinion on the correspondents.

1. Shell-entity transfer — NOT PRESENT. The only transfer is inventors → operating company (Protiva) and subsidiary → parent (Protiva → Arbutus). No "IP / Holdings / Ventures / Licensing" assignee ever appears in this chain. Arbutus is a Nasdaq‑listed corporation (ABUS), not a single‑purpose Delaware LLC, and it files 10‑Ks.

2. Known asserter in the chain — NOT PRESENT. Neither Protiva, Arbutus, nor Genevant appears on the enumerated lists (Acacia, Marathon, Intellectual Ventures, IPNav, Wi‑LAN, Mosaid/Conversant, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Erich Spangenberg entities). Caveat: Arbutus/Genevant are unquestionably frequent plaintiffs in the LNP space as of 2022–2026 — but they are asserting against direct product competitors (Moderna, Pfizer/BioNTech) on their own patented, product‑practicing technology, which is the opposite of the NPE profile.

3. Repeat correspondent across the chain — UNCLEAR (insufficient data). The only correspondent name I could recover anywhere near this family is Kilpatrick Townsend & Stockton LLP, Mailstop: IP Docketing‑22, 1100 Peachtree Street, Suite 2800, Atlanta, GA 30309 (USPTO Customer No. 20350) — this is the prosecution attorney of record on the continuation chain (appears on the 15/840,933 filing receipt and the "Power of Attorney: patent practitioners associated with Customer Number 20350"). I cannot confirm it as the assignment‑recordation correspondent, and I did not verify recurrence across the chain. A single, unconfirmed appearance by a large general‑practice IP firm is not a finding. Marked unclear; if this is on the Assignment Center abstracts, it is worth capturing properly.

4. Cascading transfers — NOT PRESENT. Two links total, both internal, both to the same corporate group. No chained LLCs, no shared registered‑agent addresses to compare.

5. Pre‑litigation transfer — NOT PRESENT. The amalgamation/recordation is February 2018. The first suit naming this patent (Arbutus + Genevant v. Moderna, D. Del. 1:22‑cv‑00252) was filed 28 February 2022 — roughly a four‑year gap, far outside the 6‑month window. The 2020‑11‑23 § 287(a) notice letter to Moderna is ~15 months after the merger. No venue/standing-motivated transfer.

6. Bankruptcy fire‑sale — NOT PRESENT. No Chapter 7/11 by Protiva, Tekmira, or Arbutus. Arbutus's 2024–2025 restructurings (40 % workforce cut in 2024, a further 57 % cut in Q1 2025 leaving 19 employees, and exit of the Warminster, PA headquarters) are cost rationalizations by a solvent, listed company, not an insolvency.

7. Privateering — UNCLEAR (partial, worth flagging). This is the only signal with any traction, and I want to be precise about why it is not a clean hit. The structure is: Arbutus retains title, grants Genevant Sciences (a Roivant Sciences subsidiary) an exclusive license with the right to sue, and co‑plaintiffs with it — while Arbutus holds ~16 % of Genevant's parent's equity and splits recoveries 80/20 under the license. That is a monetization structure with privateering flavor. Against it: (a) it is a license, not a transfer of title — the defining privateering move (operating co. sells the patent out to the NPE) did not occur; (b) Genevant is itself an operating LNP technology company descended from Arbutus's own LNP business (spun to Roivant in 2018), not a paper shell; (c) Arbutus's own 10‑K frames Genevant as "our exclusive licensee" supporting Arbutus's IP. I cannot resolve this to present on the evidence I have.

8. Defensive aggregator — NOT PRESENT. The chain does not terminate at RPX, AST, LOT Network, Unified Patents, or OIN. The patent has been actively enforced, not neutralized.

Verdict

Operating-company assertion.

The chain is inventors → Protiva Biotherapeutics (recorded 2018‑02‑21, assignment of assignors' interest) → Arbutus Biopharma Corporation (recorded 2018‑02‑21, merger/amalgamation) — two internal links with no shell, no aggregator, and no third‑party sale anywhere in it (D. Del. 1:22‑cv‑00252, Ex. B = the '359 patent; Am. Compl. §30: "All are assigned to and owned by Arbutus"). The patent is asserted by its owner against actual product competitors — Moderna (D. Del., filed 28 Feb 2022) and Pfizer/BioNTech (D.N.J., filed 4 Apr 2023) — and the asserted technology is embodied in an approved commercial product (Onpattro/patisiran, licensed to Alnylam). The four‑year gap between the 2018 recording and the first 2022 suit rules out a pre‑litigation re‑titling play, and no named entity matches any public NPE roster.

The two honest qualifications: (i) the Genevant exclusive‑license / 80‑20 split / ~16 % equity arrangement is a privateering‑shaped structure that I can only mark unclear, since title never left Arbutus; and (ii) Arbutus is today a near‑pure IP‑monetization shell of its former self (19 employees, in‑house research discontinued, 2026 capital return of up to ~$230 M from the Moderna settlement) — which explains why the assertion is happening but does not change the historical ownership character.

Verify at: ["https://assignment.uspto.gov/patent/index.html"] search patent number 8492359 — and cross‑check the legal‑events feed at ["https://patents.google.com/patent/US8492359/en"] (which is where the two 2018‑02‑21 entries above come from). I was unable to retrieve the reel/frame abstracts in this session and have not represented any reel number as verified.

I'll search for the citation record of US 8,492,359 and its prior-art references.

Good — I found the patent front page in a court exhibit. Let me retrieve the complete "References Cited" list from multiple full-text sources.

Let me pull more of the front-page citation list, including the foreign documents and the "cited by examiner" set.

Prior‑Art Citation Analysis — US 8,492,359 B2

Patent under analysis: US 8,492,359 B2, Lipid formulations for nucleic acid delivery, Yaworski et al., issued Jul. 23, 2013, application 13/253,917 filed Oct. 5, 2011, assignee Protiva Biotherapeutics, Inc. (now Arbutus Biopharma Corp.).

Scope discipline: Every reference below belongs to US 8,492,359's own record. I did not substitute results for similar numbers (e.g., 8,492,359's siblings 8,492,568/8,492,561 are not reported; the family members I mention — '069, '668, '435 — are named only to exclude them from § 102, not as substitutes).

1. Sourcing note — what I could and could not open

Two important honest limits up front:

1. The front page lists grant dates only. It does not list the filing dates of the cited patents. Since you asked for "publication/filing date," I give the verified grant/publication date for each and explicitly mark filing date as not of record rather than estimating it.
2. The front page carries no titles or abstracts for the cited patents. The descriptions below are my own subject‑matter characterizations from general knowledge of this art, flagged by confidence. I did not verify titles/abstracts reference‑by‑reference in this session, and I say so rather than overstate.

2. The (56) References Cited — U.S. Patent Documents

Transcribed as a union of the two court‑exhibit renditions, which differ by OCR errors and by two entries that appear in only one rendition. [A] = doc 42/3 only; [B] = doc 1/5 only; unflagged = present in both.

Also present on the front page but not transcribed above: a Foreign Patent Documents block and a long Other Publications (NPL) block, both truncated in what I could retrieve. The visible NPL entries are:

• Arpico, S., et al., "Preparation and Characterization of Novel Cationic Lipids Developed for Gene Transfection," Proceed. Int'l Symp. Control. Rel. Bioact. Mater. (Controlled Release Society), 1999.
• Arpico, S., et al., "Synthesis, characterization and transfection activity of new saturated and unsaturated cationic lipids," Il Farmaco, 2004, vol. 59, pp. 869‑878.
• Ballas, N., et al., "Liposomes bearing a quaternary ammonium detergent as an efficient vehicle for functional transfer of TMV‑RNA into plant protoplasts," Biochimica et Biophysica Acta, 1988.
• Barinaga, M., "Step Taken Toward Improved Vectors for Gene Transfer," Science, 1994, vol. 266, p. 1326.
• Bass, "The Short Answer," Nature, 2001, 411: 428‑9.
• Beale, G., et al., "Gene Silencing Nucleic Acids Designed by Scanning Arrays: Anti‑EGFR Activity of siRNA, Ribozyme and DNA Enzymes Targeting a Single Hybridization‑accessible Region using the Same Delivery System," J. Drug Targeting, 2003, vol. 11, No. __ (truncated).

The truncation point is meaningful: this is a siRNA‑era NPL set (Bass 2001, Beale 2003), i.e., the examiner/applicant was citing both classic lipoplex chemistry and the then‑new RNAi literature.

3. Conflicts and discrepancies I am flagging

1. OCR variants between the two court‑exhibit renditions of the same front page. These are transcription errors, not distinct references:

Per your instruction to interpret identifiers literally, I have not silently corrected these. I flag that the right‑hand column cannot all be right, and that the correct citation for each must be confirmed against USPTO PatentCenter.

1. Priority date conflict. Google Patents and the printed front page give April 15, 2008 (provisional 61/045,228) / April 15, 2009 (parent 12/424,367). The Unified Patents litigation portal entry for US‑8,492,359‑B2 shows "Priority Date: 2008‑04‑14." These differ by one day; I have not resolved it and would defer to PatentCenter. This matters because it shifts the pre‑AIA § 102(b) critical date.

2. Expiry conflict (carried forward from the earlier section, still unresolved). Google Patents: 2029‑06‑13. GreyB/Pharsight (patent listed against Onpattro/patisiran sodium): Apr 15, 2029. The Korean NGV LNP patent‑landscape table also gives 2029.04.15 for the family. Three sources vs. one; I still could not reach PatentCenter to settle it.

3. Corroboration of the earlier section's claim‑1 reconstruction. The AI‑Extracts analysis of the D.N.J. complaint in Acuitas v. Genevant, 3:23‑cv‑04200, quotes the asserted claim element "(b) a cationic lipid comprising from 50 mol % to 85 mol % of the total lipid present in the particle" — matching the '435 claim 1 language the earlier section used. This corroborates (does not verbatim confirm) the reconstruction; the '359 claim text itself remains unretrieved.

4. References that are not available as § 102 art (threshold exclusions)

Before assessing § 102, three categories must be removed:

• The '359 patent's own family / same inventive entity: 12/424,367 (issued as US 8,058,069), provisional 61/045,228, pre‑grant pub US 2012/0183581 A1, and family members US 8,822,668, US 9,364,435, US 2010/0130588 A1, WO 2009/127060, WO 2009/082817, plus later Arbutus continuations (US 11,141,378 etc.). Same inventors / common ownership; and most post‑date the critical date. These cannot be § 102 art against '359. Note that '359 is expressly "[a] continuation of application No. 12/424,367, filed on Apr. 15, 2009, now Pat. No. 8,058,069" — so the parent's disclosure is available to '359 as § 112 written‑description support, not as prior art.
• Applicant's own earlier work cited in the specification (e.g., US 2006/0083780 and US 2006/0240554, cited in the '359 description for cationic lipid synthesis; US 2004/0142025 and US 2007/0042031 for particle preparation; US 5,885,613 for PEG‑ceramide conjugates) — these are incorporated by reference, and at minimum are applicant‑origin/commonly‑owned material.
• Post‑filing art: anything published after the effective filing date is § 102(e)/(a)‑type art only if it has an earlier effective U.S. filing date; the Google Patents "Cited By" set (e.g., US 10,815,291; US 11,346,394) is downstream art and is not § 102 art against '359 at all.

Governing statute: application 13/253,917 was filed October 5, 2011, i.e., before the March 16, 2013 AIA first‑to‑file transition. The '359 prosecution therefore runs under pre‑AIA 35 U.S.C. § 102. All the U.S. patents in the table above issued between 1983 and 2003 — far more than one year before either plausible critical date — so as a class they are pre‑AIA § 102(b) art (patents/printed publications), not § 102(a)/(e) art.

5. § 102 analysis — closest candidates and claim mapping

Client‑ready conclusion first: on the face of the record, no reference cited in US 8,492,359 anticipates any claim. The patent issued over this art, and the reason is structural: every independent claim is defined by a numeric molar‑ratio window — cationic lipid 50–85 mol %, non‑cationic lipid 13–49.5 mol %, aggregation‑inhibiting conjugated lipid 0.5–2 mol % of total lipid (the "1:57" and "1:62" windows in the spec). The cited 1983–2003 art is liposome/lipoplex art that expresses its formulations as charge ratios (+/−) or weight ratios, or, where it does use mol %, uses cationic‑lipid fractions well below 50 %. A single reference therefore cannot disclose all elements "arranged as recited."

That said, a § 102 attack would be filed against the following references, in this order of strength:

5.1 Closest § 102 candidates — composition claims (claims 1 and 14)

5.2 Cell‑contact method claim (claim 15)

Claim 15 (contacting a cell with the claim‑1 particle) would be attacked with the cationic‑lipid transfection references, because those are exactly "contact a cell with lipid + nucleic acid" disclosures:

• US 5,171,678 A (Behr et al., 12/1992) and US 5,264,618 A / US 5,703,055 A (Felgner et al., 11/1993 and 12/1997) — cationic‑lipid‑mediated transfection.
• US 4,897,355 A, US 5,208,036 A, US 5,545,412 A (Eppstein et al., 1990/1993/1996) — lipid/nucleic‑acid transfection.
• US 5,283,185 A (Epand et al., 2/1994), US 5,334,761 A (Gebeyehu et al., 8/1994), US 5,736,392 A (Hawley‑Nelson et al., 4/1998), US 6,051,429 A / US 6,376,248 B1 (Hawley‑Nelson et al., 2000/2002) — cationic lipid reagents.
• US 5,641,662 A (Debs et al., 6/1997), US 5,279,833 A (Rose, 1/1994), US 5,578,475 A / US 6,020,202 A (Jessee, 1996/2000), US 6,020,526 A / US 6,034,135 A / US 6,251,939 B1 / US 6,339,173 B1 (Schwartz et al., 2000–2002) — lipid/polymer nucleic‑acid delivery.

All of these fail § 102 on claim 15 for the same reason: claim 15 incorporates the claim‑1 particle, and these references disclose lipoplexes (lipid mixed with nucleic acid) at charge or weight ratios, with no disclosure of the 50–85 / 13–49.5 / 0.5–2 mol % triple window, and generally no encapsulated‑particle architecture at all.

5.3 In vivo delivery / treatment claims (claims 16 and 17)

• US 5,705,385 A (Bally et al., 1/1998) and US 5,885,613 A (Holland et al., 3/1999) are the systemically‑administered, circulation‑stable lipid‑vesicle references and would be the named § 102 references for claim 16.
• Same failure mode: no numerical‑ratio disclosure matching claims 1/16/17.

5.4 Dependent claims (siRNA species; DPPC/DSPC; cholesterol 30–40 mol %; PEG‑DAG/PEG‑DAA)

For these, § 102 is not the realistic vehicle — a single reference in the cited list does not disclose, e.g., cholesterol at 30–40 mol % together with a 50–85 mol % cationic lipid and 0.5–2 mol % conjugate. Any serious challenge would be a § 103 combination (cationic‑lipid reference + cholesterol/PEG‑lipid reference + RNAi reference), which is why the third‑party challenge to this family was framed as an IPR obviousness attack (below). I flag this as the honest ceiling of a § 102 theory here.

5.5 Secondary evidence of what a later challenger actually treated as the art

Not part of the '359 prosecution record, but directly probative of "most relevant prior art" for this same specification: the petition in IPR2018‑00739 (directed to the sibling '435 patent, identical disclosure) relied on

• Ex. 1002 — the "'196 PCT" application;
• Ex. 1005 — Lin;
• Ex. 1006 — Ahmad;
• Ex. 1008 — Gao ("hundreds of new cationic lipids…");
• Ex. 1009 — Bennett (50 % cationic lipid formulations);
• Ex. 1012 — U.S. Patent No. 7,939,505 (cationic lipid "about 0.5 % to about 70 % (mol %)"; Example 32/Table 12 and Examples 34–35/Tables 15–18 at 50 % cationic lipid).

Two takeaways: (i) the challenged claims were attacked on § 103, with 50 %‑cationic‑lipid formulations as the hinge, confirming that no single reference disclosed the full 50–85 % window; and (ii) U.S. 7,939,505 and the Ahmad/Bennett/Gao/Lin publications are not in the '359 front‑page list I retrieved, so if you need the complete "most relevant art" picture rather than just the patent's own citation list, those are the references to pull next. I have not verified their content in this session and do not assert they anticipate anything.

6. What I did not obtain (explicit)

1. The full (56) list. Truncated at 6,586,4__ (U.S. patents) and at "Beale, G." (NPL). The Foreign Patent Documents block and the remainder of the NPL block were not retrieved — those are material omissions, since a § 102 analysis of this family would expect WO 01/05372‑type and WO 2005/007196‑type documents in that block.
2. The two PTO‑1449/892 citation lists for application 13/253,917 (filed 4/3/2013 and 6/26/2013), and the examiner‑cited list (4/3/2013). I could see they exist on the docket but could not open them.
3. Filing dates for any cited U.S. patent.
4. Titles/abstracts for the cited patents — hence the confidence flags.
5. Verbatim claim text of '359. Still reconstructed from the '435 sibling plus the D.N.J. complaint quotation.
6. The identity of 6,586,4__.

If you want the analysis hardened to a litigation‑grade element‑by‑element § 102 chart, the next pulls are: (a) PatentCenter's "References Cited" documents for 13/253,917, and (b) the full texts of 6,287,591, 6,534,484, 5,981,501, and 5,976,567 — those four carry the entire § 102 weight of the applicant‑cited list, and I expect all four to fail on the molar‑ratio limitations.

I'll ground the prior-art analysis with targeted searches before writing.

The PTAB petition material I surfaced is directly on point. Let me pin down the exhibit identifications and any parallel challenges to this family.

Analytical note on the "Prior Art" section of the fetched page

The Google Patents page for US 8,492,359 as fetched exposes only a very thin prior-art section: a "Prior art keywords" list (mol, lipid, nucleic acid, particle, sirna) and a prior art date of 2008‑04‑15. The fetched text is truncated before the "References Cited" / "Cited By" tables, so there is no reference-level prior-art listing on the page itself. I therefore grounded this analysis on (a) the reference lists that appear on the corresponding front pages as reproduced in the D. Del. litigation exhibits, and (b) the prior art that has actually been adjudicated against this specification family at the PTAB and Federal Circuit. Where I could not verify something verbatim, I say so.

Critical date. Because '359 is a continuation of 12/424,367 (issued as US 8,058,069) claiming provisional 61/045,228 filed 2008‑04‑15, pre‑AIA §102/§103 governs and the critical date is April 15, 2008. Everything cited below is §102(b) art (published 2005–2006) except where noted. Post‑April‑2008 material (e.g., Judge J. Clin. Invest. 119:661 (2009), Semple Nat. Biotechnol. 28:172 (2010), WO 2009/127060) is not prior art and I have excluded it from the grounds.

Flagged contradiction with the previously generated section. The earlier summary asserts that '359 claim 1 is (by corroborated inference from the sibling US 9,364,435) the broad three‑lipid genus: cationic 50–85 mol%, non‑cationic 13–49.5 mol%, conjugated 0.5–2 mol%. Two search results cut against extending that inference to '359:

• The Federal Circuit decision in ModernaTx v. Arbutus quotes '069 claim 1 as the sole independent claim reciting 50–65 mol% cationic plus a non‑cationic mixture of phospholipid 4–10 mol% and cholesterol 30–40 mol% — i.e., a narrower, four‑component claim.
• A Korean patent‑landscape table lists the representative claim 1 of WO 2009/127060 (the PCT counterpart of this family) as 50–65 mol% cationic with phospholipid + cholesterol (30–40 mol% cholesterol).

So the family's members do not all carry the same claim 1, and the "50–85" text is confirmed only for '435. Because the entire strength of the §103 case turns on claim breadth, I analyze both branches below and label which ground depends on which.

1. The relevant prior art and what it discloses

Formulation compositions in the family record (used below as the "trend" evidence):

2. Grounds of rejection

Ground 1 — '196 PCT in view of the '189 publication (and optionally '910)

Applies to the claim‑1‑is‑the‑broad‑genus branch.

Element‑by‑element for claim 1 as the three‑lipid genus:

Under In re Peterson, 315 F.3d 1325, 1329 (Fed. Cir. 2003), a prima facie case "typically exists when the ranges of a claimed composition overlap with ranges disclosed in the prior art." Here each of the three recited lipid ranges is expressly disclosed in a single reference, which is materially different from the '069 situation (where the fourth, phospholipid, sub‑range was not expressly disclosed and the Board refused to presume obviousness for that reason — Moderna Therapeutics v. Arbutus, IPR2019‑00554, FWD (July 23, 2020); aff'd, No. 2020‑2329 (Fed. Cir. Dec. 1, 2021)).

Ground 2 — Chen '554 alone, or '196 PCT + '554

Per the IPR2019‑00554 Ground 3, the '554 publication discloses the same four lipid classes in the same architecture (Table IV, L051 = CLinDMA:DSPC:cholesterol:PEG‑DMG). Used alone for anticipation of a narrower claim; used in combination for motivation (same problem, same components, same applicant field).

Ground 3 — Dependent‑claim‑specific art

• Phospholipid species (DPPC/DSPC): '196 PCT and '189 publication both enumerate DSPC, DPPC, DOPE, POPC, etc. (a closed list of helper lipids).
• Phospholipid 3–15 mol% / 4–10 mol%: '189 "2:40:10" example has 10 mol% DSPC; '910 examples span 6.7–20 mol% phospholipid.
• Cholesterol 30–40 mol%: 1:57 (34.3) and 1:62 (36.9) in the record; '196 teaches cholesterol as the neutral lipid.
• PEG‑DAG / PEG‑DAA, PEG‑DMA / PEG‑DSA: '196 PCT and US 2005/0118253; US 5,885,613 for PEG‑ceramide; the '359 specification itself lists PEG‑cDMA, PEG‑cDSA, PEG‑DMG, PEG‑C‑DOMG as the suitable conjugates.
• ≥1 mol% conjugate: '189 = 2 mol%; '910 tested 1 and 2 mol% PEG‑C‑DMA.

Ground 4 — Claims 14–20 (pharmaceutical composition; introduce into a cell; in‑vivo delivery; treatment)

These add no lipid limitation. Where a composition is obvious, a claim to "a composition comprising [it] and a pharmaceutically acceptable carrier," to "contacting a cell with [it]," and to "administering a therapeutically effective amount of [it] to a mammal" for the known utility (Zimmermann 2006 taught the ApoB/hepatic‑silencing utility of this exact particle class) is obvious — the method adds only the intended use of the known composition (In re Kao; MPEP 2144.08).

Ground 5 — The "1:57/1:62 as a routine extension of 2:30/2:40"

Even if one starts from the prior art working examples rather than its broad ranges, the record shows a monotonic trend in cationic lipid content (15 → 30 → 40 mol%) with the '910 publication expressly testing cationic lipid from 5–40 mol% and reporting better knockdown at higher loading, and with a constant cationic‑to‑phosphate (N/P ≈ 6) design constraint spanning both the 2:40 and 1:57 formulations. A POSITA seeking better hepatic knockdown would increase the cationic lipid fraction and ratiometrically decrease the lipid:drug ratio — which is exactly the step from 2:40 (L/D 12.5) to 1:57 (L/D 9). This is the classic KSR/"obvious to try" and In re Aller/In re Boesch "optimization of a result‑effective variable" fact pattern.

3. Motivation to combine, with a reasonable expectation of success

1. Same field, same problem, same components, overlapping inventors/assignee. '196 PCT, '189, '554, '910 and '359 share inventors (MacLachlan, Jeffs, Palmer, Lam, Yaworski) and the same SNALP architecture. KSR Int'l v. Teleflex, 550 U.S. 398 (2007), and In re Keller treat this as a strong combination rationale.
2. The prior art itself says the proportions are variables. '196 discloses express percentage ranges for every component and states the proportions may be varied; the '359 specification makes the same admission: "It should be understood that these SNALP formulations are target formulations, and that the amount of lipid (both cationic and non‑cationic) present and the amount of lipid conjugate present in the SNALP formulations may vary" (US 8,492,359, discussing the 1:57 and 1:62 formulations). Specifications' own characterizations of the claimed parameters as tunable are admissions usable against the claims.
3. Prosecution‑record admission in the family. The examiner in the '069 family found that "MacLachlan ['910 publication] … teaches that the proportions of the components can be varied by those of skill in the art. Thus, by routine experimentation towards optimization, one of skill in the art could arrive at the instantly claimed proportions." (quoted in the IPR2019‑00554 record) — an express articulation of the In re Aller rationale.
4. Defined, known functions of each lipid. Cationic lipid condenses the anionic nucleic acid and drives endosomal release; PEG‑lipid provides steric stabilization and circulation lifetime; cholesterol provides bilayer stability; phospholipid is a helper lipid. A POSITA adjusting any one has a reason to adjust the others — which is precisely the "interdependence" the Federal Circuit discussed in the '069 appeal, but which cuts for the skilled artisan's ability to titrate as well as against predictability.
5. The PEG range is taught by the art's own titration. '910 Example 20 titrates PEG‑C‑DMA at 10, 4, 2 and 1 mol% and the earlier SPLP work titrates 15, 10, 5 and 2.5 mol%; the art taught the trade‑off (more PEG = better circulation but poorer transfection). Moving to 0.5–2 mol% is the direct result of that expressly taught screen.
6. No new chemistry, no new process. Claim 1 adds a molar‑ratio window to an otherwise fully disclosed particle; every element (nucleic acid, cationic lipid, non‑cationic lipid, aggregation‑inhibiting conjugate) is separately known and known to be combinable.

4. Countervailing evidence that would defeat or materially weaken the attack

This is not a one‑sided record, and I should be explicit about that:

(a) The same obviousness theory was litigated against the parent and failed.

• IPR2019‑00554: Board held Moderna had not shown claims 1–22 of US 8,058,069 unpatentable; the Board refused to apply the Peterson/du Pont presumption because the phospholipid range was not expressly disclosed and the "overlap" required assumptions about the other components.
• ModernaTx, Inc. v. Arbutus Biopharma Corp., No. 2020‑2329 (Fed. Cir. Dec. 1, 2021): affirmed. The court held that evidence the components "interacted in an unpredictable or unexpected way could render the combination nonobvious" (In re Applied Materials), found that "the properties of nucleic acid‑lipid particles depend on the particle as a whole, rather than on any one component," and held that even treating the phospholipid range as result‑effective, Moderna failed to address the interdependence of the components.
• Consequence: if '359 claim 1 is the narrower '069‑style claim (50–65 mol% cationic + phospholipid 4–10 mol% + cholesterol 30–40 mol%), the §103 attack is substantially foreclosed by that affirmed record, which involved the same specification and the same POSITA.

(b) Unexpected results, but scope‑limited. The '359 specification asserts (and Examples 3–5 report) that the 1:57 formulation was "more than 10 times as efficacious as the 2:30 SNALP … at a 10‑fold lower dose" and that tolerability improved. That is powerful evidence of non‑obviousness — but only to the extent the claims are commensurate in scope with it. The specification's own Table 2 spans PEG 1.0–3.9 / DLinDMA 25.0–57.1 / phospholipid 5.3–18.2 / cholesterol 31.6–64.9 mol%, and the highest cationic‑lipid content actually reduced to practice is 57.1 mol%. A claim reaching 65–85 mol% cationic lipid is supported by no comparative data and by no prior‑art example. That portion of the claim is exposed: unexpected‑results evidence must be commensurate in scope with the claimed range.

(c) The '435 result — the most probative single data point, presented with a caveat. According to Law360's and Evaluate's reporting, the PTAB in September 2019 invalidated all claims of US 9,404,127 (anticipation) and, in the companion decision, upheld some claims of US 9,364,435 but invalidated that patent's sole independent claim — and the sole independent claim of '435 is the broad 50–85 / 13–49.5 / 0.5–2 mol% genus. If '359 claim 1 is that genus, this is directly adverse to '359. Caveat: I could not in this session retrieve the '435 Final Written Decision itself, confirm its IPR number (the record references "IPR2018‑00739" as a challenge on the same specification under the pre‑Phillips standard), or verify the grounds. Treat (c) as secondary‑source reporting plus inference, not verified primary text.

(d) The Board's evidentiary standard. The Board required proof of an expressly disclosed overlapping range before Peterson applies, and declined to credit "routine optimization" theories that ignored component interdependence. Any '359 petition would have to do what Moderna did not: show the artisan's expected direction and magnitude of change for the particle as a whole.

5. Bottom line

• Strongest §103 case: a three‑reference combination of WO 2005/007196 + US 2006/0134189, optionally with US 2006/0008910 and US 2006/0240554, against a broad genus claim 1 (50–85 / 13–49.5 / 0.5–2 mol%). All three lipid ranges are expressly disclosed, the reference shares inventors and architecture, and the reference itself states the proportions may be varied. Under Peterson/In re Aller/KSR, that is a prima facie case, and the demonstrated unexpected results do not reach the 65–85 mol% end of the claim.
• Weakest portion of that case: the claim's upper range (≈65–85 mol% cationic lipid) and the requirement to show a reasonable expectation of success for the particle as a whole, per Applied Materials and the affirmed '069 record.
• If '359 claim 1 instead mirrors '069 claim 1 (50–65 mol% cationic + phospholipid 4–10 + cholesterol 30–40), the same combination was already adjudicated and rejected, and the better prediction is that the claims survive §103 — with the analysis shifting to §112 (breadth/commensurate disclosure) rather than §103.
• Dependent claims (phospholipid species and mol%, cholesterol mol%, PEG‑DAG/DAA identity, ≥1 mol% conjugate, siRNA/aiRNA/miRNA types) are individually and collectively the most vulnerable, because each limitation has an express, pre‑2008 antecedent in '196, '189 ('2:40:10), '554 (L051), '910 or US 2005/0118253.
• Method claims 14–20 rise and fall with claim 1; the Zhenmermann 2006 Nature paper supplies the pre‑critical‑date therapeutic utility that makes the "administering … for treatment" claims obvious if the composition is obvious.

Residual uncertainties I am not papering over: the verbatim text of '359 claims 1–20 was not retrieved (the fetched page is truncated before the claims; my claim‑1 characterization is an inference from the '435 sibling, contradicted in part by the '069/'WO 2009/127060 records); the identities of the "Lin" and "Ahmad" references were not verified; and the '435 Final Written Decision and the '359‑specific invalidity contentions (if any) in S.D.N.Y. 1:22‑cv‑02229, D.N.J. 3:23‑cv‑04200 / 2:23‑cv‑01876, and D. Del. 1:22‑cv‑00252 were not retrieved in this session.

Sources consulted: US 8,492,359 Google Patents page (https://patents.google.com/patent/US8492359/en) for the prior‑art keywords/date and specification text; IPR2019‑00554 documents via PTACTS (https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1522819](/patent/1522819)/... and .../1507618/...); ModernaTx, Inc. v. Arbutus Biopharma Corp., No. 2020‑2329 (Fed. Cir. Dec. 1, 2021) (https://cases.justia.com/federal/appellate-courts/cafc/20-2329/20-2329-2021-12-01.pdf); IPWatchdog and Law360 coverage of the '069 FWD (https://ipwatchdog.com/2020/08/05/ptab-decides-moderna-challenge-arbutus-vaccine-patent/; https://www.law360.com/ip/articles/[1295024](/patent/1295024)/); Winston & Strawn case note (https://webiis08.mondaq.com/unitedstates/patent/[1170944](/patent/1170944)/); Arbutus v. Moderna docket materials (archive.org/gov.uscourts.ded.78146 documents 181.3, 316.4, 667.27; CourtListener dockets 63119229); Acuitas v. Genevant filing (docketalarm.com case 1‑22‑cv‑02229 doc 42‑2); US 2006/0008910 and CA2569664A1 formulation examples (Justia/Patents‑Review/Google Patents); Zimmermann et al., Nature 441:111 (2006).